Back to company

Novo Nordisk Denmark A/S: Financial statements 2018

CVR: 38180045

Novo Nordisk Denmark A/S (CVR 38180045) has filed annual accounts for 2018. In 2018, the company reported revenue of DKK 341,939,236 and a net result of DKK 4,213,051. The profit margin was 1.2%. Equity amounted to DKK 10,091,666. The solvency ratio was 7.8%. The company had 69 employees in the financial year.

Revenue
341,939,236 kr.
Gross Profit
119,226,948 kr.
Profit/Loss
4,213,051 kr.
Equity
10,091,666 kr.
Total Assets
130,040,182 kr.
Employees
69

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on Novo Nordisk Denmark A/S

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2018

Tomas Haagen joins the board of Novo Nordisk Denmark A/SOct 1, 2018

As of October 1, 2018, Tomas Haagen has joined the board of directors of Novo Nordisk Denmark A/S.

Karsten Munk Knudsen joins the board of Novo Nordisk Denmark A/SOct 1, 2018

As of October 1, 2018, Karsten Munk Knudsen has joined the board of directors of Novo Nordisk Denmark A/S.

Ole Falvig Ramsby leaves the board of Novo Nordisk Denmark A/SOct 1, 2018

As of October 1, 2018, Ole Falvig Ramsby has left the board of directors of Novo Nordisk Denmark A/S.

Karsten Munk Knudsen leaves the board of Novo Nordisk Denmark A/SSep 30, 2018

As of September 30, 2018, Karsten Munk Knudsen has left the board of directors of Novo Nordisk Denmark A/S.

Morten Berger Engelund joins Novo Nordisk Denmark A/S as directorMay 15, 2018

As of May 15, 2018, Morten Berger Engelund is registered as director of Novo Nordisk Denmark A/S.

Steffen Hillebrandt Thejls steps down as director of Novo Nordisk Denmark A/SMay 15, 2018

As of May 15, 2018, Steffen Hillebrandt Thejls has stepped down as director of Novo Nordisk Denmark A/S.

Novo Nordisk Denmark A/S publishes interim reportMay 3, 2018

Novo Nordisk Denmark A/S has published its interim report for the period November 14, 2016 – December 31, 2017.

Steffen Hillebrandt Thejls joins Novo Nordisk Denmark A/S as directorJan 1, 2018

As of January 1, 2018, Steffen Hillebrandt Thejls is registered as director of Novo Nordisk Denmark A/S.

Mads Veggerby Lausten steps down as director of Novo Nordisk Denmark A/SJan 1, 2018

As of January 1, 2018, Mads Veggerby Lausten has stepped down as director of Novo Nordisk Denmark A/S.

About Novo Nordisk Denmark A/S

Novo Nordisk Denmark A/S is a Danish company of the type Aktieselskab based in København S, founded in 2016. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Novo Nordisk Region Europe Pharmaceuticals A/S. The management consists of Mads Wilhelm Øckenholt Larsen. The company is owned by NOVO NORDISK REGION EUROPE A/S. The company has 81 employees. In 2025, the company reported revenue of DKK 2,504,841,000 and a net result of DKK 118,803,000 compared with DKK 86,129,000 the year before. Equity amounted to DKK 134,570,000.

Other financial years